According to a recent LinkedIn post from Gallant, the company is promoting an educational webinar for veterinary technicians focused on managing feline chronic gingivostomatitis. The session, led by dentistry specialist Mary Berg, also covers the emerging role of mesenchymal stromal cell therapy in refractory cases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights GallantU as a platform for continuing education, offering 1 RACE-approved CE credit to attendees. This emphasis on advanced clinical applications of cell therapy suggests Gallant may be working to deepen engagement with veterinary professionals, which could support long-term adoption of its regenerative medicine offerings.
By spotlighting mesenchymal stromal cell therapy in a practical, case-management context, the webinar may help position Gallant closer to the center of evolving standards of care in veterinary dentistry. If the company can convert educational touchpoints into product demand and brand loyalty, this strategy could modestly enhance revenue visibility and strengthen its niche in the veterinary therapeutics market.